Obeticholic Acid: A New Era in the Treatment of Nonalcoholic Fatty Liver Disease

DOI Web Site 1 Citations
  • Ludovico Abenavoli
    Department of Health Sciences, University “Magna Graecia”, Viale Europa-Germaneto, 8810 Catanzaro, Italy
  • Tetyana Falalyeyeva
    School of Medicine, Taras Shevchenko National University of Kyiv, Volodymyrska Street 64/13, 01601 Kiev, Ukraine
  • Luigi Boccuto
    Greenwood Genetic Center, Greenwood, SC 29646, USA
  • Olena Tsyryuk
    School of Medicine, Taras Shevchenko National University of Kyiv, Volodymyrska Street 64/13, 01601 Kiev, Ukraine
  • Nazarii Kobyliak
    Department of Endocrinology, Bogomolets National Medical University, Pushkinska 22a, 01610 Kiev, Ukraine

Description

<jats:p>The main treatments for patients with nonalcoholic fatty liver disease (NAFLD) are currently based on lifestyle changes, including ponderal decrease and dietary management. However, a subgroup of patients with nonalcoholic steatohepatitis (NASH), who are unable to modify their lifestyle successfully, may benefit from pharmaceutical support. Several drugs targeting pathogenic mechanisms of NAFLD have been evaluated in clinical trials for the treatment of NASH. Farnesoid X receptor (FXR) is a nuclear key regulator controlling several processes of the hepatic metabolism. NAFLD has been proven to be associated with abnormal FXR activity. Obeticholic acid (OCA) is a first-in-class selective FXR agonist with anticholestatic and hepato-protective properties. Currently, OCA is registered for the treatment of primary biliary cholangitis. However, promising effects of OCA on NASH and its metabolic features have been reported in several studies.</jats:p>

Journal

Citations (1)*help

See more

Details 詳細情報について

Report a problem

Back to top